Merck in talks with NewLink to scale up Ebola vaccine production: Bloomberg

Ebolavirus under an electron microscope--Courtesy of CDC

Merck ($MRK) may soon be the next Big Pharma to step into the Ebola vaccine arena. According to Bloomberg, it's in talks with Iowa's NewLink Genetics ($NLNK) to pitch in with the manufacturing of the company's candidate, currently in Phase I trials in the U.S. and Canada. The New Jersey giant would join peers GlaxoSmithKline ($GSK) and Johnson & Johnson ($JNJ) in the Ebola vaccine race; both of those companies are currently developing prospects of their own. More